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ABSTRACT
 
Purpose: Propose an approach of prostate cancer (PCa) patients during COVID-19 pandemic.
Material and Methods: We conducted a review of current literature related to surgical 
and clinical management of patients during COVID-19 crisis paying special attention to 
oncological ones and especially those suffering from PCa. Based on these publications and 
current urological guidelines, a manual to manage PCa patients is suggested. 
Results: Patients suffering from cancer are likely to develop serious complications from 
COVID-19 disease together with an increased risk of postoperative morbidity and mortality. 
Therefore, the management of oncological patients should be taken into special consideration 
and most of the treatments postponed.
In case the procedure is not deferrable, it should be adapted to the current situation. While 
the shortest radiotherapy (RT) regimens should be applied, surgical procedures must undergo 
the following recommendations proposed by main surgical associations.
PCa prognosis is generally favourable and therefore one can safely delay most of the biopsies 
up to 6 months without interfering with survival outcomes in the vast majority of cases. In 
the same way, most of the localised PCa patients are suitable for active surveillance (AS) or 
hormonal therapy until local definitive treatment could be reconsidered. In metastatic as well 
as castration resistant PCa stages, adding androgen receptor targeted agents (abiraterone, 
apalutamide, darolutamide or enzalutamide) to androgen-deprivation therapy (ADT) could 
be considered in high risk patients. On the contrary, chemotherapy, immunotherapy and 
Radium-223 must be avoided with regard to the consequence of hematologic toxicity and 
risk of COVID-19 infection because of immunodepression. 
Conclusions: Most of the biopsies should be delayed while AS is advised in those patients 
with low risk PCa. ADT allows us to defer definitive local treatment in many cases of 
intermediate and high risk PCa. In regard to metastatic and castration resistant PCa, 
combination therapies with abiraterone, apalutamide, darolutamide or enzalutamide could 
be considered. Chemotherapy, Radium-223 and immunotherapy are discouraged.
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INTRODUCTION
They are called Guidelines, not God’s lines
The outbreak of coronavirus that cause the 
disease COVID-19 has not only created a pandemic 
situation and a global crisis but beyond imagina-
tion, it has completely modified our way to look at 
medical information and its clinical application.
Medical Guidelines, without a doubt, are 
of utmost importance and a great deal of work 
is continuously deployed to offer our patients the 
highest level of patient care. Every society solidly 
invests on the training of the young generation 
to develop novel ideas, then exposing those ideas 
to a scientific method, eventually obtaining evi-
dence and more importantly reaching a high level 
of recommendation. Simultaneously, our younger 
peers are actively taught to verify this information 
in detail, selecting the best of it and to create a 
number of standardized practices aiming to ob-
jectively guide therapeutic options. Particularly in 
the case of oncology there are so many exceptions 
that do not necessarily fit the typical case for one 
option or another (1). In these occasions tumor 
boards and faculty discussions may provide a ra-
tional and adoptable treatment option.
Nowadays days we face an unfamiliar 
enemy, SARS-CoV-2, an RNA virus with low mu-
tational process but a high recombination poten-
tial allowing it to switch hosts in a rather timely 
fashion (2). Nevertheless, whereas we hold much 
basic knowledge on the anatomy of this new type 
of coronavirus which is able to cause severe respi-
ratory illness in 20% of patients (5% of them re-
quiring ventilation and intensive care) (3), no high 
level evidence recommendations are available to 
deal with the challenge it has created to humanity.
Today, we had no choice but to look back 
at « experience medicine » and use the creator of 
Sherlock Holmes, Sir Arthur Conan Doyle, appro-
ach to identify and solve problems. What do we 
have in our medical armamentarium that could 
deal with this threat? Researches around the World 
are dealing with this question, and of utmost im-
portance, we must understand that during this 
pandemic, cancer does not stop and some specific 
patients still need priority treatment.
Our aim is to propose an approach for 
prostate cancer (PCa) patients management during 
COVID-19 pandemic.
MATERIAL AND METHODS
We reviewed most of the ongoing recom-
mendations given by the main health, surgical 
and urological associations around the World, 
such as the World Health Organization (WHO), the 
National Comprehensive Cancer Network (NCCN), 
the European Association of Urology (EAU) and 
the British Association of Urological Surgeons (3-
6). In addition, publications related to COVID-19 
pandemic were also reviewed putting special in-
terest in those focused on surgical management 
of patients, as well as cancer, in particularly PCa.
Afterwards, the authors propose a practi-
cal guide to manage PCa during COVID-19 ou-
tbreak based on current urological guidelines. 
Such proposal is adapted to the special condition 
we face today.
RESULTS
Patient selection to perform a PCa Biopsy and 
Conditions
It has been reported that SARS-CoV-2 is 
present in the stool of COVID-19 patients and fe-
cal–oral transmission is possible. While it has not 
been demonstrated that the prostate biopsy pro-
cedure itself would be a way of COVID-19 trans-
mission, we advise to avoid or defer almost all 
prostate biopsies (7-9).
Whom to biopsy
In cases where risk factors for high risk 
PCa are present –prostate specific antigen (PSA) 
>20, PSA doubling time (PSA-DT) < 6 months, 
suspicious of clinical T3 disease, and/or local or 
systemic symptoms-, biopsy can be delayed up to 
3 months. On the other hand, in the absence of 
high risk factors, biopsy may be postponed till 3 to 
6 months later (6, 8), or even 12 months according 
to NCCN recommendations (7) (Table-1). 
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Table 1 - Management of clinical suspicion of PCa and localized PCa during the COVID-19 era.
Tumor stage Recommendations Comments
Clinical suspicion (elevated 
PSA and/or abnormal DRE)
1. Presence of High risk PCa factors
-PSA >20
- PSA-DT doubling time < 6 months
- T3 disease, and/or local or systemic symptoms
Biopsy must be delayed up to 3 months (8). 
2. Absence of High risk PCa factors
Biopsy may be postponed 3 to 6 months (8).
PCa prognosis generally 
favourable can safely delay 
most biopsies up to 6 to 12 
months without interfering 
with survival outcomes in the 
vast majority of cases (6-8).
Localized very low, low and 
risk favorable intermediate-risk 
diseases.
AS must be prioritized while RP as well as RT should be deferred. NCCN and EAU PCa guidelines 




Delay local definitive treatment
Start ADT 6-monthly formulations
Delay RP and RT may not 
imply a very high impact on 
oncological outcomes (13, 
14).
NCCN and EAU PCa guidelines 
currently recommend short 
course of ADT added to RT 
(15, 16).  
Preoperative ADT studies 
show a lack of benefit in 
prolonging overall survival 
but an improvement in 
pathological variables (17).
Localized  High-risk and very 
high-risk
Prioritize definitive treatment if it is available
Start ADT 6-monthly formulations
Consider ADT followed by RT in selected patients
Consider ADT followed by RP in selected patients
Initiation of ADT must be 
the standard of care in these 
patients until local therapy 
could be reconsidered as the 
coronavirus crisis improves 
or ends.
The benefit of neoadjuvant 
ADT has already been widely 
verified before RT (17). 
Preoperative ADT studies 
show a lack of benefit in 
prolonging overall survival 
but an improvement  in 
pathological variables (17).
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In regard to Multi-Parametric Magnetic 
Resonance Imaging (mpMRI), the EAU recommends 
upfront pre-biopsy mpMRI if resources allow. 
However, if the patient is suspected to be liable to 
risk of progression and metastasis, biopsy can be 
performed without prior MRI (6). 
Considering a possible fecal-oral CO-
VID-19 transmission no rectal lavage for prepa-
ration and complete protective personal equi-
pment (PPE) during procedure are advisable. 
Negative-pressure rooms should be utilized 
when possible (6-9). 
Patient Approach
In those patients with localized PCa, the 
two available options to treat them with curati-
ve intent, namely radiotherapy (RT) and radical 
prostatectomy (RP), must be both postponed as 
much as possible during coronavirus crisis (10, 
11). In the case of metastatic PCa patients the 
use of some systemic treatments may be com-
promised as a consequence of an increase in the 
number of visits to health centers and the risk 
of iatrogenic infection that it would entail. 
Nowadays the main question to be re-
solved is how long our patients can wait for a 
treatment without interfering with oncological 
outcomes. While this doubt is clarified we pro-
pose the following management.
Localized disease
Very low, low and risk favorable intermedia-
te-risk diseases
A recent prospective, open-enrollment 
cohort study showed a risk of cancer death or 
metastasis lower than 1% over 15yr follow-up 
in Grade Group 1 PCa patients who underwent 
Active surveillance (AS) (12). According to 
this study as well as PROTECT and PIVOT trials 
(13, 14), NCCN and European PCa guidelines 
currently recommend or propose AS as a good 
management option in this group of patients 
having favorable outcomes(15, 16). Therefore, 
AS must be prioritized while RP as well as RT 
should be deferred until restrictions to contain 
the spread of COVID-19 are over (Table-1).
Follow-up biopsies and PSA-tests should 
be postponed by > 3 months from the preplan-
ned appointment in order to decrease the num-
ber of visits to hospital and to promote social 
distancing (6).
Unfavorable intermediate risk
Despite the fact that AS for these stages 
of the disease is not contemplated in the cur-
rent guidelines (15, 16), given the extraordina-
ry situation in which we find ourselves in, RP 
and RT should be postponed with a believably 
not very high impact on specific cancer morta-
lity (13, 14).
Short course (4-6 months) of androgen-
-deprivation therapy (ADT) added to RT are 
indicated in these patients (15, 16) while ADT 
prior to RP might be considered during COVID19 
pandemic. Although it is well known that this 
last approach is not associated with survival 
benefits it is also related to better pathological 
results (17). For these reasons, we recommend 
the initiation of androgen blockage. 
In relation to the possible effect that a 
prolonged neoadjuvant treatment may have on 
oncological outcomes it has been observed that 
extending neoadjuvant ADT therapy duration 
prior to RT from 8 to 28 weeks neither signifi-
cantly improve nor worsen oncological outco-
mes on patients with unfavourable intermediate 
risk PCa (18). These results suggest that we may 
safely delay the need to definitive local treat-
ment for 4-6 months (9, 18, 19) (Table-1).
Keeping into consideration that those 
patients with a PCa grade group 3 could have 
an increased risk for eventual metastases (19) 
as well as a five-fold increased risk of PCa mor-
tality compared to grade group 2 (20), we su-
ggest to continue follow-up PSA-tests every 3 
months and provide the results by telehealth.
High-risk and very high-risk
Initiation of ADT must be the standard 
of care in these patients until local therapy 
could be reconsidered as the coronavirus crisis 
improves or ends. The benefit of neoadjuvant 
ADT has already been widely verified before RT 
(17). 
In view of a lack of benefit in prolon-
ging overall survival, current urological gui-
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delines strongly discourage the use of elective 
neo-adjuvant ADT in patients who are going 
to undergo RP outside of clinical trials (15-17). 
However, preoperative ADT studies have shown a 
significant reduction in positive surgical margins 
and downstaging along with an improvement in 
other pathological variables such as lymph node in-
volvement. Additionally, these results tended to be 
better if neo-adjuvant ADT was prolonged from 3 to 
6 or 8 months prior to surgery (17).
Intensive androgen blockage prior to RP is 
currently under study with favorable preliminary re-
sults, but further study is necessary (21).
In case of detecting patients with a rapid 
PSA-DT (≤3 months) timely therapy could be indi-
cated and the benefits of immediate treatment must 
be weighed against the risk associated to iatrogenic 
exposure to COVID-19 (11).
As long as there is a limited availability of 
operating rooms, material and human surgical re-
sources which make it impossible to perform RP, RT 
could be an alternative. Within RADS (Remote visits, 
Avoidance, Deferments, and Shortening of radiothe-
rapy) framework created by Radiation Oncologist, 
shortening of the RT treatment is the fundamental 
principle for these high risk patients without com-
promising the oncological outcomes (4, 11) (Table-1).
Like what was proposed previously for pa-
tients with unfavourable intermediate-risk PCa, we 
suggest to maintain quarterly PSA monitoring.
Unfavourable features after radical prostatectomy 
According to preliminary results from 
ARTISTIC meta-analysis presented at ESMO 
2019 Congress, event-free survival is not im-
proved with adjuvant radiotherapy (ART) com-
pared to salvage radiotherapy (SRT) in patients 
with combined high-risk features (pT3-T4/R1/
GS (8-10, 22). Despite ART remains the recom-
mended treatment option until more evidence 
to suggest otherwise (15, 16), we strongly advi-
se SRT as a safe alternative (Table-2). 
Biochemical recurrence (BCR)
The real impact of BCR in cancer morta-
lity is currently unknown whereas recent studies 
suggest that just a subgroup of patients would de-
velop progressive disease following BCR after RP 
with less optimistic results in case of RT failure. 
In this sense, patients may be stratified into EAU 
Low-Risk or High-Risk BCR according to PSA-DT, 
pathological ISUP grade and interval to biochemi-
cal failure (23).
According to the above, in case of clinical 
suspicion of BCR the authors suggest to postpone 
Table 2- Management of unfavourable features after radical prostatectomy or biochemical recurrence after local treatment 
of PCa during the COVID-19 era.
Tumor Stage Recommendations Comments
Unfavourable features after radical 
prostatectomy
Avoid adjuvant RT. According to ARTISTIC meta-
analysis, event-free survival 
is not improved with ART 
compared to SRT in patients 
with combined high-risk 
features (pT3-T4/R1/GS 
8-10) (22).
Biochemical recurrence Delay complementary studies as well as salvage 
treatments, especially in EAU low-risk cases.
Offer salvage treatment for those patients with high-
risk BCR if it is available. If not, neoadjuvant ADT 
could be considered (6).
Recent studies suggest that 
just a subgroups of patients 
would develop progressive 
disease following BCR after 
local treatment (23).
RT = Radiotherapy; ART = Adjuvant Radiotherapy; SRT = Salvage Radiotherapy; EAU = European Association of Urology BCR = Biochemical Recurrence; ADT = Androgen 
deprivation therapy
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complementary studies as well as salvage treat-
ments during COVID-19 pandemic, especially in 
Low-Risk cases. On the other hand, we propose 
to offer salvage treatment for those patients with 
High-Risk BCR if it is available. If not, neoadju-
vant ADT could be considered (6) (Table-2).
Non metastatic castration- resistant prostate 
cancer
Three randomised phase III trials, PROS-
PER, SPARTAN and ARAMIS showed a significant 
metastatic free survival benefit in non-metastatic 
castration- resistant PCa patients treated with en-
zalutamide vs. placebo, apalutamide vs. placebo 
or darolutamide vs. placebo, respectively. There-
fore, current guidelines strongly recommend these 
drugs to patients with castration- resistant PCa, 
absence of metastases and PSA-DT < 10 months. 
Taking into account that survival benefit was not 
proven after 20 months of follow-up as well as 
potential adverse events, we recommend these 
drugs in high selected patients during the CO-
VID-19 pandemic (1, 15, 16) (Table-3).
Metastatic disease
Metastatic castration- sensitive prostate cancer 
ADT must be initiated according to current 
standard of care (15, 16), with the six-month for-
mulations being the best choice (4, 5).
In regard to Intermittent ADT, it requires a 
closer PSA and testosterone monitoring in addi-
tion to possible images so it should be avoided in 
order to minimize hospital attendance.
In the last few years combination castra-
tion therapy with the new hormonal treatments 
(abiraterone, apalutamide or enzalutamide) has 
demonstrated benefits in terms of survival com-
pared to ADT alone. Abiraterone acetate and pred-
nisone or apalutamide added to ADT significantly 
reduce the risk of death by an amount equal to 28 
and 33% respectively (24, 25) while enzalutamide 
plus ADT reduces radiographic progression-free 
survival or deaths by 60% (26).
The median age of patients who are can-
didates for combination hormonal treatments is 
around 70 (24-26). Although age is a potential 
risk factor for mortality of adult inpatients with 
COVID-19 (27) and these new drugs imply a clo-
ser follow-up, agreeing with the EAU, we suggest 
to offer immediate systemic treatment within < 6 
moths as long as a correct follow-up by telemedi-
cine can be guaranteed (6).
In case the use of combined hormonal 
treatment is contemplated, we suggest to avoid 
abiraterone since the use of corticosteroids in 
population infected with SARS-CoV-2 is not yet 
completely clarified (5, 28).
With respect to chemotherapy, it must be 
avoided as much as possible being replaced by ADT 
or ADT in combination with androgen receptor 
targeted agents in order to reduce the number of 
clinical visits and haematological toxicity without 
compromising oncological outcomes (Table-4).
Metastatic castration- resistant prostate cancer 
For castration-resistant metastatic pa-
tients, ADT must be maintained. 
Abiraterone significantly improves overall 
survival among patients who previously receive 
chemotherapy compared to ADT alone. Neverthe-
less, improvement in median survival is not more 
than 5 months (29). In those patients who have 
not received chemotherapy, median overall sur-
vival is also improved from 30,3 to 34,7 months 
Table 3 - Management of non metastatic castration- resistant PCa during the COVID-19 era.
Tumor Stage Recommendations Comments
Nonmetastatic castration- resistant 
prostate cancer
Consider combination castration therapy with the new 
hormonal treatments (apalutamide, darolutamide, 
enzalutamide) in high selected patients.
These drugs have 
demonstrated benefits in 
terms of metastatic free 
survival in patients with PSA-
DT < 10 months (1, 15, 16).
PSA-DT = Prostate Specific Antigen - Doubling Time
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Table 4 - Management of metastatic PCa during the COVID-19 era.




ADT 6-months formulations must be initiated.
Avoid intermittent ADT.
Consider combination castration therapy with 
the new hormonal treatments (abiraterone, 
apalutamide or enzalutamide).
Prefer apalutamide or enzalutamide to 
abiraterone.
Avoid CTx.
ADT is the current standard of care (15,16).
Intermittent ADT requires a closer PSA and 
testosterone monitoring in addition to possible 
images.
These drugs have demonstrated benefits in terms of 
survival compared to ADT alone (24-26).
Effect of corticosteroids in population infected with 
SARS-CoV-2 is not yet clear (5, 28).
CTx is associated with hematological toxicity and 
implies multiple visits to the hospital (6).
Metastatic castration- 
resistant prostate cancer
ADT 6-months formulations must be maintained.
Consider combination castration therapy with 
the new hormonal treatments (abiraterone, 
enzalutamide).
Prefer enzalutamide to abiraterone.
Avoid CTx.
Avoid  Immunotherapy (Sipuleucel-T).
Avoid Radium-223.
Avoid starting denosumab or zoledronic acid.
In those patients under treatment,  denosumab 
may be maintained while zoledronic acid should 
be delayed.
ADT maintenance is the current standard of care (15,16).
These drugs have demonstrated benefits in terms of 
survival compared to ADT alone (29, 30-32).
Effect of corticosteroids in population infected with 
SARS-CoV-2 is not yet clear (5, 27).
CTx is associated with hematological toxicity and 
implies multiple visits to the hospital (6).
Sipuleucel-T might cause cytokine release while 
cytokines as IL-6 have been directly related to the 
most aggressive forms of COVID-19 (4, 34).
Radium-223 is associated with overall survival 
benefit by 3,6 (in the absence of visceral 
metastases) compared to ADT alone, but it is also 
associated to hematologic toxicity (35).
Denosumab or zoledronic acid have no impact on 
overall survival but could generate osteonecrosis of 
the jaw or hypocalcaemia (36, 37).
Denosumab can be administrated in its monthly 
subcutaneous formulation while zoledronic 
acid requires monthly hospital intravenous 
administration.
57
INT BRAZ J UROL | VOLUME 46, SUPPL. I, JULY, 2020
(30). Similar results are observed with enzalutami-
de plus ADT. It has been reported an improvement 
in median overall survival of  5 months in those 
patients already treated with chemotherapy(31) 
and 2 months in chemo-naïve patients (32).
In case we decide to introduce abiratero-
ne or enzalutamide, we must choose enzalutamide 
for the reasons previously mentioned (5, 27).
Chemotherapy also increases median sur-
vival in this type of patient, but we advise against 
its use during the current crisis (4-6, 33).
Cytokines as IL-6 have been directly re-
lated to the most aggressive form of COVID-19. 
Hence, Immunotherapy with sipuleucel-T whose 
more frequently adverse events involve cytokine 
release, should not be given (4, 34).
Radium-223 must be further avoided. Al-
though, it is associated with overall survival benefit 
by 3,6 months in patients with CRPC without vis-
ceral metastases compared to ADT alone, it is also 
associated to hematologic toxicity (anemia, throm-
bocytopenia and neutropenia) and monthly risk vi-
sits to hospital for intravenous administration (35).
As a result of the lack of benefit in overall 
survival with the administration of denosumab or 
zoledronic acid we propose to delay its introduc-
tion due to their potential toxicity (e.g., osteone-
crosis of the jaw, hypocalcaemia) (36, 37). In those 
cases where treatment has been already started, 
denosumab can be maintained in its monthly sub-
cutaneous administration while zoledronic acid, 
which requires monthly hospital intravenous ad-
ministration, should be delayed (Table-4).
DISCUSSION
PCa is the second most common cancer in 
men worldwide (behind lung cancer) and the first 
one in Europe with a higher incidence in develo-
ped countries as a consequence of screening pro-
grams (38). Therefore, this pathology represents 
an important percentage of the burden of work 
carried out in Uro-Oncology units, being RP one 
of the most frequent operating room procedures 
performed by urologists with a rising trend during 
recent years (39).
While the management of PCa was alrea-
dy complex and under constant debate (15, 16), 
the current global pandemic has further compli-
cated the treatment algorithm of this pathology. 
Additionally, all current recommendations are not 
based on robust evidence, but mostly expert con-
sensus. In this sense, at most the PCa treatment 
recommendations in “EAU guidelines recommen-
dations to the COVID 19 era” have level 2-3 evi-
dence (6). 
Elective definitive PCa treatments as RP as 
well as RT are being cancelled or postponed for 
an unknown time in view of the following points:
1. Patients suffering from cancer are at 
increased risk of infection and serious 
complications from COVID-19 (40).
2. Unknown SARS-CoV-2 infected pa-
tients who are asymptomatic and who 
have undergone a surgery are more li-
kely to suffer from complications with 
a mortality rate of 20.5% (41).
3. Risk of SARS-CoV-2 infection in the 
surgical team as well as patients (iatro-
genic exposure to the virus).
4. Need of hospital resources as PPE, 
Hospital/ICU beds and ventilators.
In regard to definitive treatment choice, 
we must keep in mind that replacing most of RP 
by RT could not be the universal solution. In a 
well-balanced scenario, both treatments coexist 
and resources should be adapted to needs. Sup-
posing that all patients suitable to undergo active 
treatment are treated with RT, treatment waiting 
time would be dramatically increased resulting in 
treatment delay. The potential solution may create 
a new problem. Hence, we advise to considerer RP 
as a potential curative treatment during and af-
ter COVID 19 pandemic. In this sense, it has been 
shown that in localized low and intermediate-risk 
PCa patients, 6 to 9 months of delay from biopsy 
to RP is associated to an increased risk of BCR or 
clinical recurrence at 5 years lower than 18% and 
0.6%, respectively.  While in high risk patients the 
risk of BCR is higher (close to 24% after 9-12 from 
the biopsy), short term ADT might protect them 
until surgery in 3-6 months (42). It is important 
to take into consideration that the studies which 
lead us to avoid ADT prior to RP due to a lack of 
survival benefit (neither a detriment) compared to 
immediate surgery are the same which support the 
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use of neoadjuvant ADT in those patients whose 
surgery is forced to be delayed during COVID19 
pandemic (20).
The special situation that urologists face 
today force all of us not only to think about when 
but also how we must treat our patients.
All elective visits should be postponed or 
transitioned to telehealth visits to further reduce 
exposure risk. For those patients who must be seen 
in clinic, social distancing should be promoted to 
ensure minimal contact with staffs and other pa-
tients (43).
Once SARS-CoV-2 was confirmed as glo-
bal pandemic by WHO, and community transmis-
sion was accepted, all patients must be considered 
suspected cases until proven otherwise. Therefore, 
we consider that all patients should be tested prior 
to any surgery. In case it is not possible, telephone 
interview depicting symptomatic or oligo-symp-
tomatic cases could be an alternative option (9, 
44). Additionally, in those case where abdominal 
tomography image is required, thorax imagine 
should be added at the same time.
Testing of elective patients is recommen-
ded within 48 hours prior to surgery. SARS-CoV-2 
positive patients or clinically suspected patients 
should have their CaP intervention postponed as 
far as possible (6).  
Several studies have proven transmission 
of different viruses during surgery (45, 46). Ac-
cording to a recent publication, this risk could be 
higher during laparoscopic procedures compared 
to open ones (47). This is due to the concentrated 
aerosol in the abdominal cavity formed during the 
operation being released suddenly when trocars 
are removed, small incisions are done or instru-
ments are exchanged (48). In addition, airborne 
transmission is possible through intubation and 
extubation. This fact has led the EAU Robotic Uro-
logy Section to propose some recommendations to 
safeguard the health of the surgical staff (9).
However, we shouldn’t forget that not all 
urological cancers are PCa. The extent of thera-
peutic alternatives for PCa in its different stages 
drive us to considerer all of them during the lack 
of medical and surgical resources in favour of 
non-deferrable treatments such as cystectomies, 
trans-urethral resection of high volume tumours, 
big mass nephrectomies, or orchiectomies.
CONCLUSION
As a consequence of COVID-19 pandemic 
several measures have been taken in order to re-
duce the fast spread of the virus, to protect health 
professionals from infection during their work, to 
guarantee the health of in-patients, and to ensure 
the availability of health resources to address the 
vast number of patients suffering from the coro-
navirus disease. Subsequently, clinical and surgi-
cal strategies in Urology have been forced to adapt 
to the changes brought about by COVID-19.
Since PCa prognosis is generally favora-
ble, we can safely delay most of the biopsies while 
AS must almost be mandatory in those patients 
with low risk PCa. Furthermore, the existence of 
therapeutic alternatives such as ADT allows us to 
defer definitive local treatment in many cases of 
intermediate and high risk PCa, assuming a be-
lievably not too significant impact on oncologi-
cal outcomes. In regard to metastatic castration 
resistant PCa, combination therapies with novel 
drugs such as abiraterone, apalutamide, darolu-
tamide or enzalutamide should be considered in 
high risk diseases whereas their secondary effects 
could be managed by telehealth. Chemotherapy or 
Radium-223 must be avoided because of haema-
tological toxicity and frequent hospital visits. We 
advise against the use of Sipuleucel-T given the 
risk of cytokines reaction.
Nevertheless, each PCa case must be con-
sidered individually and the proposed recommen-
dations should constantly adapt to the epidemio-
logical evolution of the situation.
ABBREVIATIONS
PCa = Prostate Cancer
CRPC = Castration Resistant Prostate Cancer
RT = Radiotherapy
RP = Radical Prostatectomy
ADT = Androgen Deprivation Therapy
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